Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP: DMTTF )

0.1273 +0.0160 (+14.38%)
Streaming Delayed Price Updated: 3:29 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 227,091
Open 0.1254
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1113
Today's Range 0.1118 - 0.1273
52wk Range 0.0450 - 0.1905
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... 
Via Benzinga
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). 
Via Benzinga

Performance

YTD
+74.38%
+74.38%
1 Month
+154.60%
+154.60%
3 Month
+144.81%
+144.81%
6 Month
+142.94%
+142.94%
1 Year
-2.08%
-2.08%

More News

Read More
Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Via Benzinga
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Via Benzinga
Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M
Via Benzinga
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via Benzinga
Cybin to Acquire Small Pharma Inc.
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin to Acquire Small Pharma Inc.
From Cybin Inc.
Via Business Wire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
Via Benzinga
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
Via Benzinga
Small Pharma Reports Fiscal First Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
Via Benzinga
Small Pharma Implements Costs Cut: New R&D Strategy And Management Team Change
Via Benzinga
Small Pharma Announces SPL028 R&D Strategy Update
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Management Team Change
From Small Pharma Inc.
Via GlobeNewswire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Via Benzinga
Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses
Via Benzinga
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
From Small Pharma Inc.
Via GlobeNewswire
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Via Benzinga
Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World
Via Benzinga
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
From Small Pharma Inc.
Via GlobeNewswire
DMT For Major Depression Shows Remarkable Benefits After Six-Month Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.